MEDIA CENTER - 2010 & 2011

November 21, 2011
Biotech Finances, a French electronic magazine specializing in reporting global biotech financing news publishes article on APIM Therapeutics (Issue 527, November 21; see www.biotech-finances.com). A copy of the article (in French) can be downloaded here.

November 10, 2011
APIM Therapeutics announced today conclusion of a third seed follow-up financing round led by Scandinavian investment companies Birk Venture and Ro Invest in syndication with Sarsia Seed, a seed stage investor that has already led two investment transactions in APIM Therapeutics. Financing will be used to further advance the preclinical development of APIM Therapeutics' anti-cancer lead compound in selected tumor indications including blood cancer and solid tumors. For more information, please visit the following web site link: http://www.prnewswire.co.uk/cgi/news/release?id=339330 

March 21, 2011
APIM Therapeutics announced today conclusion of a second seed follow up financing round by Sarsia Seed, a Norwegian seed stage life science fund. Financing will be used to advance the preclinical investigation of APIM Therapeutics' lead compound in further cancer in vivo studies, predominantly in Myeloma and Acute Myeloid Leukemia. For more information, please visit: http://www.prnewswire.co.uk/cgi/news/release?id=315415

May 27, 2010
APIM Therapeutics announced today that Sarsia Seed, a Norwegian seed stage life science fund, has invested NOK 3.5 million (€ 440.000) in APIM Therapeutics. The company, a spin-out from the Norwegian University of Science and Technology (NTNU), is developing novel peptide drugs which have the potential to improve clinical outcomes achieved with a large group of existing first line chemotherapeutics.

Visit Media Center 2017 & 2018
Visit Media Center 2015 & 2016
Visit Media Center 2013 & 2014
Visit Media Center 2012

Trondheim

APIM Therapeutics AS is a spin-off from the Norwegian University of Science and Technology (NTNU).

Visit our About Us page to find out more.

About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see www.ntnu.no.

About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit www.sarsiaseed.com to find out more.

About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit www.televenture.no to find out more.